vs
博士伦健康（BHC）与Take-Two Interactive（TTWO）财务数据对比。点击上方公司名可切换其他公司
博士伦健康的季度营收约是Take-Two Interactive的1.6倍（$2.8B vs $1.7B），博士伦健康净利率更高（-3.7% vs -5.5%，领先1.8%），Take-Two Interactive同比增速更快（24.9% vs 9.3%），博士伦健康自由现金流更多（$403.0M vs $236.2M），过去两年博士伦健康的营收复合增速更高（14.0% vs 10.2%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
Take-Two Interactive是总部位于美国纽约的电子游戏控股企业，由瑞安·布兰特于1993年9月创立，在全球互动娱乐领域拥有较高影响力，业务覆盖游戏研发、发行与运营等核心环节。
BHC vs TTWO — 直观对比
营收规模更大
BHC
是对方的1.6倍
$1.7B
营收增速更快
TTWO
高出15.7%
9.3%
净利率更高
BHC
高出1.8%
-5.5%
自由现金流更多
BHC
多$166.8M
$236.2M
两年增速更快
BHC
近两年复合增速
10.2%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $1.7B |
| 净利润 | $-103.0M | $-92.9M |
| 毛利率 | — | 55.7% |
| 营业利润率 | 17.0% | -2.3% |
| 净利率 | -3.7% | -5.5% |
| 营收同比 | 9.3% | 24.9% |
| 净利润同比 | -205.1% | 25.8% |
| 每股收益（稀释后） | $-0.30 | $-0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCTTWO
| Q4 25 | $2.8B | $1.7B | ||
| Q3 25 | $2.7B | $1.8B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.5B | $1.4B | ||
| Q2 24 | $2.4B | $1.3B | ||
| Q1 24 | $2.2B | $1.4B |
净利润BHCTTWO
| Q4 25 | $-103.0M | $-92.9M | ||
| Q3 25 | $179.0M | $-133.9M | ||
| Q2 25 | $148.0M | $-11.9M | ||
| Q1 25 | $-58.0M | $-3.7B | ||
| Q4 24 | $98.0M | $-125.2M | ||
| Q3 24 | $-85.0M | $-365.5M | ||
| Q2 24 | $10.0M | $-262.0M | ||
| Q1 24 | $-64.0M | $-2.9B |
毛利率BHCTTWO
| Q4 25 | — | 55.7% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 62.8% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | — | 55.9% | ||
| Q3 24 | — | 53.8% | ||
| Q2 24 | — | 57.6% | ||
| Q1 24 | — | 33.5% |
营业利润率BHCTTWO
| Q4 25 | 17.0% | -2.3% | ||
| Q3 25 | 23.1% | -5.5% | ||
| Q2 25 | 17.5% | 1.4% | ||
| Q1 25 | 12.2% | -238.7% | ||
| Q4 24 | 21.8% | -9.7% | ||
| Q3 24 | 12.7% | -22.0% | ||
| Q2 24 | 16.2% | -13.8% | ||
| Q1 24 | 13.1% | -193.9% |
净利率BHCTTWO
| Q4 25 | -3.7% | -5.5% | ||
| Q3 25 | 6.7% | -7.5% | ||
| Q2 25 | 5.8% | -0.8% | ||
| Q1 25 | -2.6% | -235.5% | ||
| Q4 24 | 3.8% | -9.2% | ||
| Q3 24 | -3.4% | -27.0% | ||
| Q2 24 | 0.4% | -19.6% | ||
| Q1 24 | -3.0% | -207.4% |
每股收益（稀释后）BHCTTWO
| Q4 25 | $-0.30 | $-0.50 | ||
| Q3 25 | $0.48 | $-0.73 | ||
| Q2 25 | $0.40 | $-0.07 | ||
| Q1 25 | $-0.16 | $-21.27 | ||
| Q4 24 | $0.24 | $-0.71 | ||
| Q3 24 | $-0.23 | $-2.08 | ||
| Q2 24 | $0.03 | $-1.52 | ||
| Q1 24 | $-0.17 | $-17.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $2.4B |
| 总债务越低越好 | $20.8B | — |
| 股东权益账面价值 | $-554.0M | $3.5B |
| 总资产 | $26.4B | $10.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BHCTTWO
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.7B | $2.0B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $719.0M | $879.6M | ||
| Q2 24 | $595.0M | $1.1B | ||
| Q1 24 | $733.0M | $776.0M |
总债务BHCTTWO
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
股东权益BHCTTWO
| Q4 25 | $-554.0M | $3.5B | ||
| Q3 25 | $-565.0M | $3.4B | ||
| Q2 25 | $-764.0M | $3.5B | ||
| Q1 25 | $-1.2B | $2.1B | ||
| Q4 24 | $-1.3B | $5.7B | ||
| Q3 24 | $-1.2B | $5.8B | ||
| Q2 24 | $-1.2B | $6.0B | ||
| Q1 24 | $-1.1B | $5.7B |
总资产BHCTTWO
| Q4 25 | $26.4B | $10.0B | ||
| Q3 25 | $26.8B | $10.1B | ||
| Q2 25 | $27.3B | $9.7B | ||
| Q1 25 | $26.4B | $9.2B | ||
| Q4 24 | $26.5B | $12.7B | ||
| Q3 24 | $26.5B | $13.1B | ||
| Q2 24 | $26.5B | $12.9B | ||
| Q1 24 | $26.9B | $12.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $305.2M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $236.2M |
| 自由现金流率自由现金流/营收 | 14.4% | 13.9% |
| 资本支出强度资本支出/营收 | 3.3% | 4.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $487.8M |
8季度趋势，按日历期对齐
经营现金流BHCTTWO
| Q4 25 | $495.0M | $305.2M | ||
| Q3 25 | $405.0M | $128.4M | ||
| Q2 25 | $289.0M | $-44.7M | ||
| Q1 25 | $211.0M | $279.0M | ||
| Q4 24 | $601.0M | $-4.8M | ||
| Q3 24 | $405.0M | $-128.4M | ||
| Q2 24 | $380.0M | $-191.0M | ||
| Q1 24 | $211.0M | $-8.9M |
自由现金流BHCTTWO
| Q4 25 | $403.0M | $236.2M | ||
| Q3 25 | $314.0M | $96.5M | ||
| Q2 25 | $190.0M | $-69.8M | ||
| Q1 25 | $96.0M | $224.9M | ||
| Q4 24 | $495.0M | $-48.2M | ||
| Q3 24 | $334.0M | $-165.2M | ||
| Q2 24 | $302.0M | $-226.1M | ||
| Q1 24 | $129.0M | $-55.1M |
自由现金流率BHCTTWO
| Q4 25 | 14.4% | 13.9% | ||
| Q3 25 | 11.7% | 5.4% | ||
| Q2 25 | 7.5% | -4.6% | ||
| Q1 25 | 4.2% | 14.2% | ||
| Q4 24 | 19.3% | -3.5% | ||
| Q3 24 | 13.3% | -12.2% | ||
| Q2 24 | 12.6% | -16.9% | ||
| Q1 24 | 6.0% | -3.9% |
资本支出强度BHCTTWO
| Q4 25 | 3.3% | 4.1% | ||
| Q3 25 | 3.4% | 1.8% | ||
| Q2 25 | 3.9% | 1.7% | ||
| Q1 25 | 5.1% | 3.4% | ||
| Q4 24 | 4.1% | 3.2% | ||
| Q3 24 | 2.8% | 2.7% | ||
| Q2 24 | 3.2% | 2.6% | ||
| Q1 24 | 3.8% | 3.3% |
现金转化率BHCTTWO
| Q4 25 | — | — | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 38.00× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
TTWO
暂无分部数据
